Medical/Pharmaceuticals
FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis
RALEIGH, N.C., Sept. 21, 2021 /PRNewswire/ -- Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents. LEXETTE, a super potent topical corticosteroid, is now approved for the treatment ...
2021-09-21 22:00
4172
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
The solution offers superior ease of formulation, potential application versatility, and more comprehensive immune support compared to probiotics and other immune health ingredients SANTA CLARA, Calif., Sept. 21, 2021 /PRNewswire/ -- Based on its recent analysis of the North American immune hea...
2021-09-21 20:00
1344
Farrer Park Hospital Enhances Dementia services to Better Guide Management and Care Plan for People with Dementia
SINGAPORE, Sept. 21, 2021 /PRNewswire/ -- Farrer Park Hospital
2021-09-21 08:15
2342
Fullerton Health launches DigiHealth Kiosk to improve accessibility and affordability of healthcare for Migrant Workers
SINGAPORE, Sept. 21, 2021 /PRNewswire/ -- The COVID 19 Pandemic has shown the
importance of primary care for all segments of society, including Migrants
Workers.
2021-09-21 07:00
2663
Novavax to Participate in Fireside Chat at Devex @ UNGA 76
GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced thatJohn J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Busin...
2021-09-21 04:46
6654
RhoVac announces the completion of patient recruitment for the BRaVac clinical phase IIb study of RV001 in prostate cancer
STOCKHOLM, Sept. 21, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onSep 20th , 2021, that its clinical phase IIb study of lead drug candidate RV001 in prostate cancer, BRaVac, is deemed fully recruited and that no additional patients will be ...
2021-09-21 04:06
1514
Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021
MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was present...
2021-09-20 22:51
6650
ZEISS Introduces a Series of Major Innovations and Industry-First Software Applications as Part of the ZEISS Medical Ecosystem
A fully connected and integrated approach keeps ZEISS at the forefront of ophthalmology with new data management innovations across devices, workflow solutions and software applications. JENA, Germany and DUBLIN, Calif., Sept. 20, 2021 /PRNewswire/ -- At ZEISS Innovation Week,September 21- 23, 2...
2021-09-20 22:00
2087
PharmAbcine to Participate in BIO-Europe 2021
DAEJEON, South Korea, Sept. 20, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in the 27th annual BIO-Europe which will tak...
2021-09-20 20:00
1172
CStone presents clinical data from the China registrational bridging study on ivosidenib in patients with relapsed/refractory acute myeloid leukemia (R/R AML) with a susceptible IDH1 mutation at the 2021 ESMO Congress
* The data showed that ivosidenib demonstrated clinical efficacy in the treatment of Chinese adults with R/R AML with a susceptible IDH1 mutation. And ivosidenib was well tolerated and had a manageable safety profile * In August 2021, the National Medical Products Administration (NMPA) of Chin...
2021-09-20 20:00
3669
Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial
* Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder * Phase 2 clinical trial on target to start by end of 2021 and expected to read out topline data by end of 2022 ADELAIDE, Australia, Sept....
2021-09-20 18:00
3470
P&G partners with Philippine Red Cross for COVID-19 Bakuna Buses in CALABARZON
MANILA, Philippines, Sept. 20, 2021 /PRNewswire/ -- Procter & Gamble (P&G)
Philippines continues stepping up as a force for good by supporting the
Philippine Red Cross (PRC) mission to assist in the government's national
COVID-19 vaccination program.
2021-09-20 15:09
1747
India Ministry of Health and Family Welfare Approves Exablate Neuro Focused Ultrasound Platform
HAIFA, Israel and MIAMI, Fla., Sept. 20, 2021 /PRNewswire/ -- Insightec
2021-09-20 11:30
1486
Terumo celebrates 100-year anniversary in Asia with an eye to the future
SINGAPORE, Sept. 20, 2021 /PRNewswire/ -- Terumo, a global leader in medical technology, celebrates its centenary inAsia. From humble beginnings as a thermometer manufacturer in 1921, and the first company in 1963 to create disposable syringes inJapan, the company has been providing medical solut...
2021-09-20 10:00
2697
Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO
SHANGHAI, Sept. 19, 2021 /PRNewswire/ -- On September 19, 2021, CARsgen Therapeutics (stock code: 2171.HK) disclosed the latest progress of the investigator-initiated trial (IIT) of Claudin18.2 (CLDN18.2) CAR-T (CT041) for the treatment of digestive system tumors. Results of this trial have been ...
2021-09-20 08:24
7121
Illumina reaffirms commitment to the National Project of Bio Big Data in Korea
MELBOURNE, Australia, Sept. 20, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the National Project of Bio Big Data in Korea has selected Illumina technology for the second pilot project in their effort to work towards establishing a national digital library on health and...
2021-09-20 07:00
4587
Qynapse Unveils Strategic Rebrand To Support Accelerated Growth And New Corporate Vision
BOSTON, Sept. 20, 2021 /PRNewswire/ -- Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, unveils a full rebrand including new logo and a complete website redesign, intended to better reflect the comp...
2021-09-20 06:00
2076
New Zealand's Cancer Organisations Warn Of COVID Pandemic-led Drop In Cancer Being Diagnosed And Treated
* Growing concern that people are reluctant to see their doctor about troubling symptoms during current uncertain period. This follows last year's lockdown which saw a decline in diagnosis of cancer across Aotearoa.[1] * Around 9,000 New Zealanders die of cancer every year.[2] * New campai...
2021-09-20 06:00
1678
CStone presents preliminary results from a phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with the anti-PD-1 mAb CS1003 in patients with advanced solid tumors at ESMO 2021
SUZHOU, China, Sept. 19, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative cancer immunotherapies and precision medicines, today announced the preliminary results from t...
2021-09-19 09:00
3468
2021 CSCO | Henlius will Release Four Oral Presentations of Two Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab and Bevacizumab Biosimilar
SHANGHAI, Sept. 18, 2021 /PRNewswire/ -- The 24th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) will be held online and in-person from 25th to 29th September 2021. In this meeting, Henlius will release 4 study results of 2 products to be commercialized, the novel anti-PD-1 mAb ser...
2021-09-18 20:00
11500
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 282 media titles]
2024-04-18 21:26
Animated Life in Yunnan
[Picked up by 278 media titles]
2024-04-18 14:00
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 277 media titles]
2024-04-19 13:25
Most Read
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
4118
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3829
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
2024-04-15 08:00
3092
Goldpac Exhibits at InnoEx 2024
2024-04-13 10:00
3032